Botox Cosmetic expands beyond face for the first time as FDA approves the anti-wrinkle therapy for treating platysma bands.

With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

AbbVie CEO Robert Michael told analysts during the company's second-quarter earnings call in July that “our ex-Humira growth ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...

AbbVie (ABBV) reachead $188.57 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.

The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of AbbVie (NYSE:ABBV) with a Market Perform ...